BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $16 from $20 and keeps a Neutral rating on the shares ...
Reports Q4 revenue $165.0M, consensus $164.98M. “In 2024, we launched major new products across all three of our platforms and we made changes ...
The "Genomic Data Analysis and Interpretation Market Opportunities and Strategies to 2033" report has been added to ...
Companies like Complete Genomics, Illumina, and Singular Genomics Systems lead the way in next-generation sequencing (NGS), while Eurofins Scientific and PCR Biosystems focus on diagnostics. Cancer, ...
and Singular Genomics Systems lead the way in next-generation sequencing (NGS), while Eurofins Scientific and PCR Biosystems focus on diagnostics. Cancer, chronic diseases, and rare disorder ...